Indinavir concentrations and antiviral effect

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 708-712

  Acosta, Edward P ^a   Henry, Keith ^a   Baken, Leslie ^a   Page, Linda M ^a   Fletcher, Courtney V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE;

EID: 0033001617     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.708.31544     Document Type: Article

References (19)

1. Carpenter CCJ, Fischl MA, Hammer S, et al. Antiretroviral therapy for HIV infection in 1997: recommendations of an international panel. JAMA 1997;277:1962-9.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N Engl J Med 1997;337:725-33.
3. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochrome P450. J Pharmacokinet Biopharm 1996;24:461-73.
4. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabol Rev 1997;29:413-580.
5. Kawle SP, Remmel RP, Weller D, Fletcher CV, A simultaneous HPLC assay for quantitation of indinavir, saquinavir, ritonavir, and nelfinavir in human plasma [abstr]. Presented at 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5, 1998.
6. D'Argenio DZ, Schumitzky A, Wolf W. Simulation of linear compartment models with application to nuclear medicine kinetic modeling. Comput Methods Prog Biomed 1988;27:47-54.
7. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75
8. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
9. Merck & Co., Inc. Indinavir (Crixivan) package insert. West Point, PA;1996.
10. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998;42:332-8.
11. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
12. Hertogs K, Mellors JW, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates [abstr]. In: Program and abstracts of the 5th conference on retrovirus and opportunistic infections, Chicago, February 1-5, 1998.
13. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998;72:5303-6.
14. Wegner S, Mascola J, Barile A, et al. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy naive individuals [abstr]. In: Program and abstracts of the 6th conference on retroviruses and opportunistic infections, Chicago, January 31-February 4, 1999.
15. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10:485-92.
16. Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis 1998;177:1514-20.
17. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
18. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;2:760-6.
19. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir. AIDS 1997;11:F95-9.